LEXINGTON, Mass.--(BUSINESS WIRE)--Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced the launch of Simoa 2.0, its next-generation ultrasensitive immunoassay platform. Simoa 2.0 addresses many customer requests and input collected during the rapid growth of Simoa’s first year and a half on the market, and includes numerous improvements to hardware and software refinements and overall instrument usability.
The Simoa 2.0 improvements will be available to all current Quanterix customers with a simple upgrade procedure and will be offered at no cost to ensure all users can benefit from the upgrades without any additional investment or interruption of their research. The upgrade includes numerous hardware and software advances and a comprehensive training program to ensure customers benefit from the many new features and capabilities. A number of beta customers around the world have already adopted Simoa 2.0 over the last few months and reported remarkable improvements in assay robustness, overall performance, reliability and ease of use.
“We have experienced rapid adoption of Simoa since our launch last year and have listened carefully to our customers’ feedback on our 'game changing' fully-automated, ultrasensitive protein detection platform,” said Kevin Hrusovsky, CEO and Executive Chairman at Quanterix. “Based on feedback, we have made an unprecedented investment to further improve the platform, including increasing assay robustness, improving multiplex capabilities, reducing sample size and enhancing overall usability of the technology. We are providing these important advances at no charge to our existing customers and have incorporated these developments into our Simoa 2.0 offering. We are excited to launch this new system and look forward to hearing customer reaction at our upcoming San Francisco customer forum.”
Quanterix will be showcasing Simoa 2.0 at their user conference taking place on October 29, 2015 in South San Francisco, CA. To register for the event, please visit: http://quanterix.com/events-news/user-groups/item/730-proteins-powering-nexgen-healthcare-san-francisco.
To learn more about the new Simoa 2.0 platform, please register for the company’s webinar on November 5, 2015 here: Simoa 2.0: Enabling the Next Generation of Protein Measurements.
Quanterix is a developer of ground-breaking tools in high definition diagnostics. Its Simoa platform uses single molecule measurements to access previously undetectable proteins. With this unprecedented sensitivity and full automation, Simoa offers significant benefits to both research and clinical testing applications. Quanterix was established in 2007 and is located in Lexington, Massachusetts. To learn more about Quanterix and Simoa, please visit: www.quanterix.com.